Online inquiry

IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5059MR)

This product GTTS-WQ5059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Hidradenitis suppurativa (HS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5059MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8653MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ9699MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ12955MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ13085MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ6478MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ7678MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ5759MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ12114MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW